News

The round involved a syndicate of leading international life sciences investors led by Novartis Venture Fund and Columbus Venture Partners, and including Roche Venture Fund, HealthCap, Kurma Partners

The randomized, double-blind, placebo-controlled study of Imeglimin administered twice-daily for 24 weeks, demonstrated dose-dependent efficacy on two key measures of diabetes control in 299 Japanese patients. The trial

Emricasan is an investigational, oral and pan-caspase inhibitor intended to treat NASH with advanced fibrosis (scarring) and cirrhosis. It has been evaluated in around 650 patients in 16 clinical

A separate sNDA was also accepted for XELJANZ XR (tofacitinib citrate) extended release 11 mg once daily use in PsA. The sNDA submission is based on data from

Sosei will make an upfront strategic investment of GBP 35 million into MiNA Therapeutics in return for a 25.6% equity share and an exclusive option to potentially acquire

Under the deal terms, Boston-based Pieris will receive $57.5m of upfront and near-term milestone payments from AstraZeneca. Pieris will advance its lead candidate, PRS-060, an anticalin against interleukin-4 receptor alpha

This license agreement is related to two targets currently under development by Novartis. The agreement includes Celyad’s intellectual property rights under United States Patent No. 9,181,527 related to

Imfinzi is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or whose disease

Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion